Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06965036 · ClinicalTrials.gov registry record
Risk Factors and Outcomes of Ischemic Stroke Associated With Tandem or Isolated Cervical Artery Occlusion in Anterior and Posterior Circulation
A clinical trial of Acute Ischemic Stroke Related to Tandem Occlusion and Acute Ischemic Stroke Due to Isolated Cervical Artery Occlusion, sponsored by Azienda Unità Sanitaria Locale della Romagna.
- Active
- Registry status
- 2,880
- Enrollment target
- 3
- Study locations
NCT06965036 is a study of Acute Ischemic Stroke Related to Tandem Occlusion and Acute Ischemic Stroke Due to Isolated Cervical Artery Occlusion that is active but no longer recruiting, run by Azienda Unità Sanitaria Locale della Romagna. The registered enrollment target is 2,880 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT06965036, a study of Acute Ischemic Stroke Related to Tandem Occlusion and Acute Ischemic Stroke Due to Isolated Cervical Artery Occlusion, is active but no longer recruiting, sponsored by Azienda Unità Sanitaria Locale della Romagna.
- ACTIVE NOT RECRUITING
- Registry status
- 2,880 participants
- Enrollment target
- 3
- Study locations
Study Summary
CERES-TANDEM is a multicenter study designed to improve the understanding of "tandem" ischemic stroke -those caused by two blockages in series, one in a neck artery and one in a brain artery-. Because tandem occlusion-related stroke tend to cause more severe brain injury and have been under-represented in major clinical trials, there is no clear consensus on which treatments work best. This study will help identify who is most at risk and which therapies lead to the best recovery. OBJECTIVES: Identify Risk Factors: Compare common stroke risk factors (e.g., high blood pressure, diabetes, high cholesterol, smoking) in patients with tandem occlusion versus those with single-site large vessel occlusions. Compare Clinical Outcomes of Reperfusion: Evaluate whether acute reperfusion treatments-such as clot-dissolving drugs (thrombolysis), mechanical clot removal (thrombectomy), and emergent carotid stenting-lead to better 3-month functional outcome (assessed by the modified Rankin Scale, ranging 0 to 6, with good functional outcome identified with mRS score 0-2) compared to medical management alone in tandem occlusion and isolated cervical artery occlusion. Assess Post Stent Therapy: Among patients who receive emergent stenting, determine whether different post-stenting regimens (antiplatelet agents, anticoagulants, or no additional therapy) affect functional outcomes, bleeding events, or stroke recurrence. STUDY DESIGN: Type: cohort study pooling data from prospective registries of cerebrovascular diseases at participating sites Setting: Stroke Unit, Cesena Hospital (PI MR), Interventional Neuroradiology, Vall d'Hebron Research Institute, Barcelona (PI FD), Radiology, Boston Medical Center (PI TN); and other participating stroke centers Time Frame: Patients treated between 2018 and 2024. Sample Size: Approximately 2800 cases overall DATA COLLECTION: Sources: Clinical records, imaging reports (CT perfusion, angiograms), lab results, hospital discharge summaries, an
Conditions Studied
Study Locations (3)
Other
- Bufalini Hospital Comprehensive Stroke Center - Cesena
- Vall d'Hebron Institut de Recerca - Barcelona
Massachusetts
- Boston Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,880 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2026-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06965036
The ClinicalTrials.gov registry entry for NCT06965036 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 2,880 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Azienda Unità Sanitaria Locale della Romagna, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Acute Ischemic Stroke Related to Tandem Occlusion appearing as the primary indexed condition, and to 0 interventions.
NCT06965036 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Other, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06965036 about?
NCT06965036 is a clinical study titled "Risk Factors and Outcomes of Ischemic Stroke Associated With Tandem or Isolated Cervical Artery Occlusion in Anterior and Posterior Circulation". CERES-TANDEM is a multicenter study designed to improve the understanding of "tandem" ischemic stroke -those caused by two blockages in series, one in a neck artery and one in a brain artery-. Because tandem occlusion-related stroke tend to cause more severe brain injury and have been under-represen...
What is the current status of trial NCT06965036?
This trial is currently active not recruiting. The enrollment target is 2,880 participants. The study started on 2018-01-01. Estimated completion is 2026-10-01.
What conditions does trial NCT06965036 study?
This clinical trial studies the following conditions: Acute Ischemic Stroke Related to Tandem Occlusion, Acute Ischemic Stroke Due to Isolated Cervical Artery Occlusion.
Who is sponsoring clinical trial NCT06965036?
This trial is sponsored by Azienda Unità Sanitaria Locale della Romagna, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06965036 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Acute Ischemic Stroke Related to Tandem Occlusion
All registered trials for this condition
Acute Ischemic Stroke Due to Isolated Cervical Artery Occlusion
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.